Displaying 761 - 780 of 1557
FTC Staff Comment To Centers For Medicare and Medicaid Services Regarding "CY2015 Policy and Technical Changes to the Medicare Advantage and Prescription Drug Benefit Programs"
FTC Staff Opinion: Rx Program Operated for the Benefit of Non-Profit Schools, Colleges, and Universities Appears to Fall within the NPIA Exemption to Robinson-Patman
FTC Staff Paper: State Legislators Should Carefully Evaluate Proposals to Limit Advanced Practice Registered Nurses’ Scope of Practice
FTC Approves Final Consent Settling Charges that Accretive Health Failed to Adequately Protect Consumers’ Personal Information
Follow-On Biologics Workshop: Impact of Recent Legislative and Regulatory Naming Proposals on Competition
Provider of Medical Transcript Services Settles FTC Charges That It Failed to Adequately Protect Consumers’ Personal Information
FTC Puts Conditions on Thermo Fisher Scientific Inc.’s Proposed Acquisition of Life Technologies Corporation
FTC Puts Conditions on Endo Health Solutions’ Acquisition of Boca Life Science Holdings
Statement of FTC Chairwoman Edith Ramirez on the U.S. District Court in the District of Idaho Ruling in the Matter of the Federal Trade Commission and the State of Idaho v. St. Luke’s Health System Ltd. and Saltzer Medical Group, P.A.
FTC Staff: Massachusetts Should Consider Removing Physician Supervision Requirements for Nurse Practitioners and Nurse Anesthetists
FTC Requires Community Health Systems, Inc. to Divest Two Hospitals as a Condition of Acquiring Rival Hospital Operator
Statement of Commissioner Maureen K. Ohlhausen Dissenting in Part and Concurring in Part
Accretive Health Settles FTC Charges That It Failed to Adequately Protect Consumers’ Personal Information
FTC Approves Final Order Settling Charges That Mylan, Inc.’s Acquisition of Agila Specialties Global Pte. Ltd and Agila Specialties Pvt. Ltd. Was Anticompetitive
Mylan Inc., Agila Specialties Global Pte.Limited, Agila Specialties Private Limited, and Strides Arcolab Limited, In the Matter of
Under a settlement with th FTC, Mylan, Inc., and Agila Specialties Global Pte. Ltd and Agila Specialties Pvt. Ltd. (collectively, Agila) divested 11 generic injectable drugs as a condition of allowing Mylan’s proposed acquisition of Agila from Strides Arcolab Ltd. (Strides). According to the complaint, in each of these 11 markets, Mylan and Agila are two of only a limited number of current or likely future competitors. The number of suppliers in generic pharmaceutical markets matters because prices generally decrease as the number of competing generic suppliers increases. In addition, the injectable generic products of concern are highly susceptible to supply disruptions caused by the inherent difficulties of producing sterile liquid drugs.
FTC Approves Final Order Settling Charges that Actavis, Inc.’s Acquisition of Warner Chilcott plc Would Be Anticompetitive in Four Current and Future Drug Markets
Displaying 761 - 780 of 1557